Sex Med Rev July 2020 PMID 31326359

A Review of Economic Evaluations of Erectile Dysfunction Therapies.

Michael E Rezaee, Charlotte E Ward, Eileen R Brandes, Ricardo M Munarriz, Martin S Gross

Mentions

7
Peak: 2 in Aug 2019
across 3 sources since Aug 2019

Extended reach

5,203
potential audience

Total likes

4

Video views

0

Mentions per month

Aug 2019 – Aug 2025

Where it's discussed

  • X / Twitter4 posts
  • News2 articles
  • YouTube1 videos

AI synopsis

What people are saying

The overall tone demonstrates moderate engagement with terms like 'reviewed the published data' and highlighting the importance of the economic evaluation of ED treatments, such as sildenafil and other interventions. The focus on uncertainties and future research needs indicates an acknowledgment of the article's significance, using words like 'cost-effectiveness' and 'underexplored' that emphasize awareness of ongoing knowledge gaps.

AgreementModerate agreement

Most discussions agree on the importance of reviewing economic evaluations related to erectile dysfunction therapies, recognizing its relevance in healthcare decision-making.

InterestModerate interest

The posts show moderate interest, focusing on key points like cost-effectiveness and the need for further research, but lack deep exploration.

EngagementModerate engagement

Posts reference the article, mention specific issues like the rising prevalence of ED, and highlight the importance of economic analysis, indicating moderate engagement.

ImpactModerate impact

The discussions reflect an understanding that the article emphasizes gaps in current research and the potential implications for clinical practice, suggesting a mild to moderate impact.

Abstract in brief

  • Erectile dysfunction (ED) is a common and expensive condition that becomes more prevalent with age, but the cost-effectiveness of its treatments across different groups of men is not well understood.
  • Most research has focused on the economic evaluation of phosphodiesterase-5 inhibitors like sildenafil, while less is known about the cost-effectiveness of other treatments such as injections, surgeries, or devices, especially in diverse patient populations.
  • Current economic studies are outdated, often do not account for modern costs, patient health variations, or different healthcare systems, highlighting the need for further research to better guide treatment choices worldwide.]

Top posts

Most liked on X and Bluesky
ASESA
@ASESAorg · X

En este estudio, se han revisado los datos publicados disponibles sobre la evaluación #económica de las terapias para la #disfunción #eréctil. Accede al artículo en: https://t.co/rcZJTJotEW https://t.co/Atty41Lrqz

Dec 3, 2020 · 3 likes · 1 share · 1,717 followers View post →
DoctorPeinado
@doctorpeinado · X

Erectile dysfunction (ED) is a common and costly urologic condition with increasing prevalence as men age. Cost-effectiveness of ED therapies and whether cost-effectiveness varies for different populations of men remains underexplored. https://t.co/yBurrPnDku vía @urotoday

Aug 11, 2019 · 1 like · 1,924 followers View post →
SCU
@scurologia · X

RT @ASESAorg: En este estudio, se han revisado los datos publicados disponibles sobre la evaluación #económica de las terapias para la #dis…

Dec 3, 2020 · 1 share · 1,503 followers View post →
USPhysioMED
@USPhysioMED · X

#peyroniedisease #doctorreferral A Review of Economic Evaluations of Erectile Dysfunction Therapies. https://t.co/PoJ9s3OIiy

Aug 3, 2019 · 55 followers View post →

All mentions

SCU
@scurologia · X

RT @ASESAorg: En este estudio, se han revisado los datos publicados disponibles sobre la evaluación #económica de las terapias para la #dis…

Dec 3, 2020 · 1 share · 1,503 followers View post →
ASESA
@ASESAorg · X

En este estudio, se han revisado los datos publicados disponibles sobre la evaluación #económica de las terapias para la #disfunción #eréctil. Accede al artículo en: https://t.co/rcZJTJotEW https://t.co/Atty41Lrqz

Dec 3, 2020 · 3 likes · 1 share · 1,717 followers View post →
DoctorPeinado
@doctorpeinado · X

Erectile dysfunction (ED) is a common and costly urologic condition with increasing prevalence as men age. Cost-effectiveness of ED therapies and whether cost-effectiveness varies for different populations of men remains underexplored. https://t.co/yBurrPnDku vía @urotoday

Aug 11, 2019 · 1 like · 1,924 followers View post →
USPhysioMED
@USPhysioMED · X

#peyroniedisease #doctorreferral A Review of Economic Evaluations of Erectile Dysfunction Therapies. https://t.co/PoJ9s3OIiy

Aug 3, 2019 · 55 followers View post →